On June 6, 2014, the United States Judicial Panel on Multidistrict Litigation established MDL No. 2545.
Lawyers for Plaintiffs, representing folks injured by Testosterone drugs, favored consolidation of all testosterone manufacturers into one MDL proceeding. The Defendants’ positions varied, with several Defendants, including AbbVie Inc. and Abbott Laboratories Inc. , Eli Lilly and Co. and Lilly USA LLC, and Endo Pharmaceuticals, supporting the establishment of an all-testosterone replacement therapy MDL in the Northern District of Illinois. Defendants Actavis, Inc., Auxilium Pharmaceuticals, Inc., Pfizer, Inc. and Pharmacia & Upjohn Co. all generally opposed the creation of an MDL consolidating all testosterone products and argued alternatively that the MDL should only include testosterone gel products.
” The Panel quoted the January 31, 2014, U.S. Food and Drug Administration (FDA) announcement that it is currently investigating the risk of stroke, heart attack, and death in men taking testosterone drugs approved by the FDA.